Bio Nanotechnology
11 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Bio Nano Consulting
Scoop.it!

Biosensors - An Introduction by Anthony Turner

A brief introduction to the field of Biosensors including the main types of device, the market size and future perspectives. Particular empahasis is placed o...
more...
No comment yet.
Scooped by Bio Nano Consulting
Scoop.it!

Platinum Capital to Launch Two Global Nanotechnology Indices - Packet Online

Platinum Capital to Launch Two Global Nanotechnology Indices Packet Online (1888 PressRelease) Platinum Capital, a boutique investment firm, today announced the company will formally launch its own global nanotechnology indices - PCG...
more...
No comment yet.
Rescooped by Bio Nano Consulting from Wearable tech and biosensors for learning
Scoop.it!

Biosensors to monitor U.S. students' attentiveness

Biosensors to monitor U.S. students' attentiveness | Bio Nanotechnology | Scoop.it
DENVER (Reuters) - The Bill & Melinda Gates Foundation, which has poured more than $4 billion into efforts to transform public education in the U.S., is pushing to develop an engagement pedometer.

Via Celine Llewellyn-Jones
more...
No comment yet.
Scooped by Bio Nano Consulting
Scoop.it!

Fighting Cancer with Nanomedicine - Scientist

Fighting Cancer with Nanomedicine - Scientist | Bio Nanotechnology | Scoop.it
Scientist
Fighting Cancer with Nanomedicine
Scientist
Given these and other issues associated with treatment safety and efficacy, scientists are applying tremendous effort toward the utilization of nanomedicine in the fight against cancer.
more...
No comment yet.
Scooped by Bio Nano Consulting
Scoop.it!

Global Nanomedicine Market Projected to be Wort...

Global Nanomedicine Market Projected to be Wort... | Bio Nanotechnology | Scoop.it
A new market research report by Transparency Market research sheds light on the growing scope of the Nanomedicine Market globally, and provides an in-depth analysis of the potential growth areas, restraints, region-wise revenue share, and much more.
more...
No comment yet.
Rescooped by Bio Nano Consulting from Industry Research Reports
Scoop.it!

Mature Biotech: Biotechnology & Pharmaceutical Industry Outlook 2014

Mature Biotech: Biotechnology & Pharmaceutical Industry Outlook 2014 | Bio Nanotechnology | Scoop.it
Check for Discount on Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech report by MP Advisors. Positive sentiments for the biotech sector have prevailed in...

Via isha3994
more...
isha3994's curator insight, January 21, 2014 3:24 AM

Global Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech


Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com  with (Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech) / report name in subject line and your contact details.       

    

Positive sentiments for the biotech sector have prevailed in the last two to three years, and the reseacrh expect this trend to continue for the next year too.  The report optimism is based on the continuity in the flow of innovative products from their pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats – which all lend stability to the business model of the company.  Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space.

 

Complete report of 72 Pages is available @ http://www.reportsnreports.com/reports/273310-global-pharmaceutical-biotechnology-outlook-2014-mature-biotech.html.


In the next five years the distinction between some mature biotech companies and large global pharma may become blurred esp. if there is consolidation within the sector.  AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira’s infliximab – Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway is defined in US.

The detailed 72 pages report contains the detailed discussion of the key attributes of leading biotech companies’ Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex.

 

Table Of Contents

Macro Analysis
Key Attributes of Leading Biotech Companies
New Drug Approval in 2013-16
Key Milestones during 2014/15
Merger and Acquisitions
Biosimilars in developments

Inquiry Before Buying on this Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=273310

 

In-depth Company Analysis and Reports on

1.Acorda Therapeutics – Pipeline of NDDS Drugs tar geting Niche Indications

Marketed Products - Ampyra and Qutenza
Label expansion of Ampyra
Pipeline beyond Ampyra

 

2. Alexion Pharma – Focus on Innovative Drugs for Orphan/Ultra-rare Diseases With No Competition Visible!


Product Pipeline – Future Potential
Soliris in PNH and aHUS: Growth to Continue
Soliris beyond PNH and aHUS
Diversifying Beyond Soliris - Asfotase alfa
Early stage programs – Cyclic Pyranopterin Monophosphate,ALXN1007,ALXN1 102

 

3. Amgen – Late-Stage Pipeline Carries Potential to Counteract Expected Headwinds
Late-Stage Pipeline
Biosimilar Opportunity & Competition
Partnership and Acquisitions
Competitive Landscape: Anti-PCSK9 mAb – Hyperlipidemia

 

4. Biogen Idec – Near Term Growth Prospects Driven by Core Business + New Product Launches
TECFIDERA
Long-Acting Hemophilia Drugs – ELOCTATE and ALPROLIX
Detailed data from long-lasting recombinant FVIII and FIX
Superiority of Gazyva against Rituxan in CLL
BIIB’s MS Franchise – Strengthening its Leadership
MULTIPLE SCLEROSIS – INJECTABLE DRUGS DATA COMPARISON
MULTIPLE SCLEROSIS – ORAL DRUGS DATA COMPARISON

 

5. Celgene – Innovative Strategies for Long Term Gains
Growth from marketed products and label expansion of Revlimid,ABRAXANE,
POMALYST/IMNOVID,Vidaza
Novel Early Stage Products - Sotatercept,ACE-536, CC-292, MOR202, CC-223,EPZ5676, CC-220
Collaborations

 

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=273310.


6. Gilead Sciences – Poised to Emerge as a Leader in HCV Treatment
Sofosbuvir/ Ledispavir FDC
Development Pipeline
HIV Life cycle management
Beyond Anti-Virals – Idelalisib, Momelotinib, Simtuzumab, GS-9973
Acquisitions
Technology platform – Dual-Afnity Re-Targeting (DART)

 

7. Regeneron – Label Expansion Sustains Eylea’s Growth Momentum + Late Stage Pipeline
Potential Poised For Further Contribution
Marketed Products – Eylea, Arcalyst, ZALTRAP
Label expansion of Eylea in DME and BRVO indication
Late-Stage Pipeline - Alirocumab, Sarilumab, Dupilumab
REGN-Sano Collaboration
BRANCH RETINAL VEIN OCCLUSION (BRVO): CLINICAL DATA ANALYSIS
COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB – HYPERLIPIDEMIA

 

Buy a copy of report http://www.reportsnreports.com/purchase.aspx?name=273310.


8. Vertex Pharma – Focus Shift to Cystic Fibrosis and Niche Indications
Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation
Small But Meaningful Addition in Other Mutations for KALYDECO
PhII data from KALYDECO / VX-809
PHIII studies for KALYDECO and VX- 809/KALYDECO in homozygous CF pts
HCV Glory Faded Very Soon
Beyond CF and HCV – VX-509, VX-787, VX-767
KEY Pipeline Products: IFN-Free Combinations for HCV

 

Industry Tables
1. Pipeline Potential Thru 2018
2. Marketed Products’ Potential
3. Sector Selected Companies M&A Activities
4. Expected Drug Clinical Milestones

 

Browse more report on Pharmaceuticals


Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Global Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech” report OR for any other market research and intelligence needs you may have for your business.